INTRODUCTION
Misoprostol (Cytotec, Searle) is a prostaglandin E 1 analogue, a methyl-ester of prostaglandin E 1 additionally methylated at C-16. It is registered in Republic of South Africa (RSA), for prophylaxis and treatment of peptic ulcer disease caused by non-steroidal anti-inflammatory drugs (prostaglandin inhibitors). In addition, misoprostol is an effective myometrial stimulant of pregnant uterus, selectively binding to EP-2/EP-3 prostanoid receptors (1) . Mariani-Neto et al. (2) first reported using oral misoprostol (400µg four hourly), for the induction of labour following IUFD. All the 20 patients delivered. However, along with its effectiveness, the authors described cases of excessive uterine activity with its use at term. Many subsequent studies have shown that misoprostol is effective, easy to use and a cheap drug for induction of labour (3) (4) (5) , in women with IUFD. However, the preferred route of administration of misoprostol is still uncertain. Three trials compared oral and vaginal misoprostol using different doses (6) (7) (8) , and their results were inconsistent.
Misoprostol is rapidly absorbed orally and vaginally(9). Zieman et al. (9) in a randomised comparison of absorption kinetics of 400µg of oral and vaginal misoprostol showed that the plasma concentration of misoprostol after oral administration, rose quickly, reaching a peak (227 pg/ml) 34 minutes after administration, fell steeply by 120 minutes and remained low for the duration of the study. In contrast, plasma concentration of misoprostol acid in subjects who received vaginal misoprostol rose gradually reaching a peak (165 pg/ml) at approximately 80 minutes after administration and declined slowly, to an average of 61% of the peak level at 240 minutes after administration. The objective of this study was to compare the efficacy of oral versus vaginal misoprostol for the induction of labour in women with IUFD after 20 weeks of gestation.
MATERIALS AND METHODS
Thirty eight pregnant women with IUFD were asked to participate in a randomised clinical trial where the vaginal and oral routes of administration of misoprostol were compared. The study was conducted at Ga-Rankuwa hospital, MEDUNSA, which serves a mainly black indigenous population. Prior to entry to the trial, confirmation of IUFD was made by ultra sound examination. Written informed consent was obtained from each woman before randomisation. Only women with a confirmed IUFD, singleton pregnancy, cephalic presentation and parity less than five were asked to participate. Women with a malpresentation, foetal macrosomia, previous uterine scar, any contra indications to receiving prostaglandin and renal or hepatic dysfunction were specifically excluded.
Randomisation was performed using sealed opaque envelopes containing a piece of paper indicating the route of administration. These envelopes were placed in a box from which the women picked one at random. The researcher did not participate in the packing of the envelopes. All patients participating in the study were admitted in antenatal ward. The initial assessment included patients' demographic features: (age, parity, gestational age), duration of IUFD and an initial Bishop score. The gestational age was calculated from the last normal menstrual period and the duration of IUFD from the date of last foetal movement perception.
Misoprostol 200 micro grams was administered six hourly orally or vaginally (in the posterior fornix), for a maximum of four doses, or until labour was established. Patients who progressed to active labour were transferred to labour ward and managed accordingly. Oxytocin augmentation was commenced six hours after the last dose of misoprostol if the patient was not yet in established labour, using an established standard oxytocin regime of 2 units, 8 units, 16 units in one litre 5% dextrose at 15 drops, 30 drops and 60 drops per minute respectively (i.e. 2 mU, 4 mU, 8 mU, 16 mU, 32 mU and 64 mU per minute respectively), increments at half hourly intervals.
The primary outcome measure was the induction to delivery time, and secondary outcome measures were the number of patients requiring augmentation with oxytocin and all complications were noted. If the woman was not in established labour six hours after commencement of oxytocin, the induction was deemed a failure.
Standard statistical methods (p-value; Odds Ratio and 95% Confidence Interval) were used to analyse the data. The study was conducted, following approval by the MEDUNSA Ethics Committee and the Chief Superintendent of the hospital.
RESULTS
Thirty eight women were randomised for the study, of whom 18 received oral misoprostol and 20 vaginal misoprostol. Both groups were comparable with respect to maternal age, parity, gestational age at the time of foetal demise, duration of the intra-uterine death, and Bishop score at commencement of induction (Table 1 ). There were no cases in which labour could not be induced. There were no post randomisation exclusions, and no woman withdrew from the trial after consent had been given. The mean induction to delivery time was 21.4 ± 13.9 hours in the oral group and 13.5 ± 8.3 hours in the vaginal (p< 0.05; Table 2 ). A higher mean dose of misoprostol was required for successful induction in the oral group (537.5 ± 249 µg) than in the vaginal group (420 ± 233µg) but this difference was not statistically significant. In addition, more women in the oral group required oxytocin augmentation 10 (55%) patients than in the vaginal group four (20%) patients (p< 0.05; Odds Ratio 2.8; 95% Cl 1.36-4.24;) ( Table 2.) There were no major complications but only minor systemic side effects namely: vomiting, diarrhoea, shivering and pyrexia, these were more common in the oral group (44.5%) than in the vaginal group (20%), (p> 0.05; Odds Ratio 2.2; 95% Cl 1.6 -2.8; Table 3 . There were no cases of uterine rupture.
DISCUSSION
In this study, the mean induction to delivery time was significantly shorter in the vaginal group (13.5 ± 8.3 hours) when compared to the oral group (21.4 ± 13.9 hours). Furthermore significantly more women in the oral group required oxytocin augmentation 10 (55.6%) of 18 patients than in the vaginal group four (20%) of 20 patients (p< 0.05). The doses of misoprostol used in this present trial were higher (200µg six hourly) than in other trials (6, 8) .
Topozada et al. (6) compared vaginal versus oral misoprostol for induction of labour in 40 women who were randomised into two equal groups. Group I received vaginal misoprostol (100µg) every three hours while group II patients were given the same dose via the oral route. The vaginal route of administration induced a higher success rate in a shorter time interval using a lower dose, but was associated with more abnormal foetal heart rate pattern and instances of uterine hyper-stimulation. The authors recommended the use of the vaginal approach with cardio-tocographic monitoring.
Wing et al. (7) in a randomised clinical trial comparing 50µg misoprostol administered orally and 25µg misoprostol intra-vaginally, 220 subjects were randomised, 110 in each arm of the study. Significantly fewer subjects who received the oral preparation (30.9%) were delivered vaginally within 24 hours of initiation of induction, in comparison with those who received the vaginal preparation (47.3%). The average interval from start of induction to vaginal delivery was nearly six hours longer in the oral treatment group (mean and SD 1737.9 ± 845.7 minutes) than in the vaginal treatment group (mean and SD 1393.2 ± 767.9) (p =0.005). Orally treated patients required significantly more doses than vaginally treated patients (orally administered doses; mean and SD = 3.3 ± 1.7; vaginally administered doses: mean and SD= 2.3 ± 1.2) with a p-value <0.0001. Furthermore oxytocin administration was necessary in 83 of 110 (75.4%) orally treated subjects and in 65 of 110 (59.1%) vaginally treated subjects (p =0.01). These authors concluded that oral administration of 50µg doses of misoprostol appears less effective than vaginal administration of 25µg doses of misoprostol for cervical ripening and labour induction.
They recommended further investigation to determine whether orally administered misoprostol should be used for cervical ripening and labour induction. Adair et al.(8) on the other hand did not find any significant difference in the efficacy in a randomised double blind trial comparing 50µg of vaginal misoprostol and 200µg of oral misoprostol for labour induction. The most important side effects of misoprostol are nausea, vomiting and dose dependent diarrhoea, stomach-ache and flatulence (10) .
In this trial significantly more side effects were reported in the oral misoprostol group with, in order of frequency; vomiting, shivering and pyrexia being the most common. Hofmeyr, et al. (11) in a randomised placebo controlled trial of oral misoprostol in the third stage of labour, using oral misoprostol 400µg, found that shivering was more common in the misoprostol group (19% vs 5%, relative risk 3.69; 95% confidence interval 2.05 -6.64). They concluded that shivering was a specific side effect of misoprostol administered orally in the puerperium. Lumbiganon, et al. (12) reported misoprostol dose-related shivering and pyrexia in the third stage of labour. Comparing misoprostol 400µg versus misoprostol 600µg both shivering and pyrexia (temperature >38°C) were more common in the 600µg misoprostol group (28% and 7.5% for shivering and pyrexia, respectively) compared with 400µg misoprostol (19% and 2%).
There was no case of uterine rupture in this study. However, this study did not aim to test the safety of the different routes of administration of misoprostol. Misoprostol causes potent uterine contractions and these can lead to hyper-stimulation of the uterus and eventually to uterine rupture. The effect of uterine hyper-stimulation is most important when misoprostol is used to induce labour where there is a live foetus. In the case of IUFD, uterine rupture is still of concern. However, the number of women required to test the comparative safety of the two routes of administration would be too large for one institution to answer.
